

2017

Conference Program



Alberta Society of
Gastroenterology

ALBERTA DIGESTIVE DISEASE SUMMIT



May 26-28, 2017 • Chateau Lake Louise • Lake Louise, Alberta



Steering Committee

Chair: Anand Bala, Grey Nuns Hospital

Robert Bailey, Royal Alexandra Hospital

Tara Chalmers-Nixon, Elk Valley Hospital/Crowsnest Pass Hospital


Carla Coffin, University of Calgary

Christian Turbide, University of Calgary

Maitreyi Raman, University of Calgary



Alberta Society of
Gastroenterology



- Demonstrate state-of-the-art knowledge in the diagnosis and treatment of liver disease, inflammatory bowel disease and other gastrointestinal issues
- Articulate and integrate into their daily practice the key findings of current research into objective monitoring for patients with Crohn's disease and ulcerative colitis, new treatments for IBD during pregnancy, and techniques for the management of Barrett's esophagus and nonalcoholic fatty liver disease
- Describe practical colonoscopy techniques for the detection, assessment and treatment of colorectal tumours
- Define the interactions between diet and the human microbiome on a case to case basis, what role they play in the development of gastrointestinal inflammation and liver-related disorders, and then employ current therapeutic advancements in microbiome manipulation
- Distill and apply in a clinical perspective the latest and most salient information presented during prominent international meetings in the fields of gastroenterology, hepatology, and nutrition studies
- Build their network of basic and clinical investigators in order to promote translational and clinical research relating to gastrointestinal disease

2017

SCHEDULE AT A GLANCE

FRIDAY PM, MAY 26	
11:30 am	Family Lunch / <i>Lago Restaurant</i> Delegate Lunch / <i>Heritage Hall</i>
12:00 noon	Symposium
12:30 pm	Reaching New Horizons with Biosimilars in IBD <i>Mount Temple C</i>
1:00 pm	Concurrent Sessions
1:30 pm	Nurses' Course <i>Mount Temple A</i>
2:00 pm	Best Practice Abstracts Review Course <i>Mount Temple C</i>
2:30 pm	Break
3:00 pm	Break
3:30 pm	
4:00 pm	
4:30 pm	Break
5:00 pm	Keynote
5:30 pm	Alcoholic Liver Disease: A Tale of Two Maladies <i>Mount Temple C</i>
6:00 pm	Family Social Event - BBQ Dinner and Dance <i>Brewster Dance Barn</i>
SATURDAY AM, MAY 27	
7:00 am	Delegate Breakfast / <i>Heritage Hall</i>
7:30 am	Symposium
8:00 am	Managing Crohn's Disease: Has It Just Become Easier? <i>Mount Temple C</i>
8:30 am	Plenary Session #1
9:00 am	
9:30 am	Excellence in Clinical Management: Part 1 <i>Mount Temple C</i>
10:00 am	
10:30 am	
11:00 am	Plenary Session #2
11:30 am	Focus on Canadian Research and Clinical Practice <i>Mount Temple C</i>
12:00 noon	

SATURDAY PM, MAY 27	
12:30 pm	Family Lunch <i>Lago Restaurant</i>
1:00 pm	Delgate Lunch <i>Heritage Hall</i>
1:30 pm	Concurrent Symposia
2:00 pm	Implementation of HCV Elimination Strategies <i>Mount Temple A</i>
2:30 pm	MED Talks - IBD Evolution <i>Mount Temple C</i>
3:00 pm	Concurrent Meetings
3:30 pm	ASG Annual General Meeting <i>Mount Temple A</i>
4:00 pm	Fellows' Exam Prep Course <i>Lakeshore/Beehive</i>
4:30 pm	Free Time
5:00 pm	Reception <i>Victoria Foyer</i>
5:30 pm	Alberta Society of Gastroenterology Awards Night and Dinner <i>Victoria Ballroom</i>
6:00 pm	Keynote: This Wild Spirit: Women in the Rocky Mountains of Canada
SUNDAY AM, MAY 28	
7:00 am	Delegate Breakfast / <i>Heritage Hall</i>
7:30 am	Concurrent Symposia
8:00 am	Only if HCV Was So Simple <i>Mount Temple A</i>
8:30 am	Keep CALM and Treat-To-Target <i>Mount Temple C</i>
9:00 am	Plenary Session #3
9:30 am	IBD at the Summit. Keeping Your Clinical Practice at Its Peak <i>Mount Temple C</i>
10:00 am	Plenary Session #4
10:30 am	Excellence in Clinical Management: Part 2 <i>Mount Temple C</i>
11:00 am	Conference Closing
11:30 am	Delegate Travel / Lunch on Own

2017 SCIENTIFIC PROGRAM

Speaker biographies are available online at <http://www.albertagastro.ca/>

Friday, May 26, 2017

11:30 - 12:00 noon Family Lunch
 Delegate Lunch

Lago Restaurant
Heritage Hall

Symposium

12:00 - 1:00 pm **Reaching New Horizons
 with Biosimilars in IBD**

Mount Temple C

Moderator: Remo Panaccione, University of Calgary

12:00 - 12:15 pm **The Technical Skinny on Biosimilars
 How, What, Why?**

Remo Panaccione, University of Calgary

Objectives:

- Review the similarities to originator molecules
- Define extrapolation and illustrate how extrapolation guides the use in IBD

12:15 - 12:30 pm **Biosimilar infliximab - The Hungarian Experience
 that Alberta Needs to Know**

*Peter Lakatos, Semmelweis University, Hungary /
 McGill University*

Objectives:

- Discuss the experience European countries had with the introduction of biosimilar Infliximab.
- Describe the quality, safety, and efficacy data of biosimilar Infliximab

12:30 - 12:45 pm **Anti-TNFs: Still the Best First Line Therapy for
 IBD Treatment**

Karen Kroeker, University of Alberta

Objectives:

- Discuss the role of anti-TNF therapy as first line in both Crohn's disease and ulcerative colitis

12:45 - 1:00 pm **Discussion: Effectiveness of the Biosimilar and
 the Value-Added Infusion Networks across Alberta**

*This symposium was co-developed with
 Pfizer Canada Inc. and was planned to achieve
 scientific integrity, objectivity and balance.*



Concurrent Sessions

1:00 - 4:30 pm

Best Practice Abstracts Review Course

Mount Temple C

Moderators: Anand Bala, Grey Nuns Hospital; Maitreyi Raman, University of Calgary; and Carla Coffin, University of Alberta

Objectives:

At the end of this session participants will be able to:

- Cite many of the highest impact abstracts in clinical gastroenterology and hepatology in 2016-17
- Translate emerging research in gastrointestinal and liver disease into improved therapeutic approaches and disease-management strategies in their clinical practice
- Describe the relevance of emerging science on daily clinical practice
- Integrate novel therapies in clinical practice
- Incorporate state of the art therapies in daily endoscopy
- Implement novel educational strategies in teaching GI fellows

1:00 - 1:05 pm

Opening Remarks

1:05 - 1:17 pm

Four Selected Abstracts Relevant to Crohn's Disease

Shaan Siffledeen, University of Alberta

1:17 - 1:22 pm

Q&A

1:22 - 1:34 pm

Greatest Hits in Pediatric GI

Jason Silverman, University of Alberta

1:34 - 1:39 pm

Q&A

1:39 - 1:51 pm

Updates in Hepatitis B and C

Carla Coffin, University of Calgary

1:51 - 1:56 pm

Q&A

1:56 - 2:08 pm

The Best GI Nutrition Abstracts in 2016/2017

Melanie Stapleton, University of Calgary

2:08 - 2:13 pm

Q&A

2:13 - 2:25 pm

What is New in Esophageal Motility Disorders

Daniel Sadowski, University of Alberta

2:25 - 2:30 pm

Q&A

2:32 - 2:42 pm	State of the Art Therapeutic Updates in UC <i>Michael Stewart, University of Calgary</i>
2:42 - 2:47 pm	Q&A
2:47 - 3:00 pm	Break
3:00 - 3:12 pm	Latest Advances in Non-Viral Liver Diseases (NAFLD and AI Hepatitis) <i>Juan Gonzalez-Abraldes, University of Alberta</i>
3:12 - 3:17 pm	Q&A
3:17 - 3:29 pm	Education Advances Relevant to GI Trainees <i>Karen Kroeker, University of Alberta</i>
3:29 - 3:34 pm	Q&A
3:34 - 3:46 pm	Best Basic Science Abstracts with Clinical Relevance <i>Humberto Jijon, University of Calgary</i>
3:46 - 3:51pm	Q&A
3:51 - 4:03 pm	Four Abstracts of RCTs That May Change Your Practice <i>Michel Sauve, Northern Lights Regional Health Centre</i>
4:03 - 4:08 pm	Q&A
4:08 - 4:20 pm	Therapeutic Endoscopy - State-of-the-Art Updates for Clinical Practice <i>Rajveer Hundal, Chinook Regional Hospital</i>
4:20 - 4:25 pm	Q&A
4:25 - 4:30 pm	Closing Comments
4:30 - 5:00 pm	Break

*Moderators: Christian Turbide, University of Calgary;
and Bobbi Sheppy, South Health Campus*

1:00 - 1:05 pm

Opening Remarks

1:05 - 1:25 pm

How To Get a Patient Off of Their PPIs

Christian Turbide, Foothills Medical Centre

Objectives:

- Determine the drivers of GERD
- Discuss why should patients not stay on a PPI long term
- Develop a strategy to help educate the patient

1:25 - 1:30 pm

Q&A

1:30 - 1:50 pm

Understanding Biosimilars

Marie-Louise Martin, Alberta Health Services

Objectives:

- Discuss the similarities between biosimilars and the reference biologic
- Develop familiarity with the approval process for biosimilars
- Identify and address common myths and current controversies relating to biosimilars

1:50 - 1:55 pm

Q&A

1:55 - 2:15 pm

Updates in Capsule Endoscopy

Tara Green, Alberta Health Services

Objectives:

- Recognize current indications for capsule endoscopy
- Recognize potential risks associated with capsule endoscopy
- Review 2017 Clinical Practice Guidelines for Use of Capsule Endoscopy

2:15 - 2:20 pm

Q&A

2:20 - 2:45 pm

Endoscopy Quiz

Nauzer Forbes, University of Calgary

Objectives:

- Review the endoscopic presentations of common clinical conditions encountered in gastroenterology
- Discuss evidence-based approaches to endoscopic therapy

2:45 - 3:00 pm

Break

3:00 - 3:20 pm

Dietary Fiber in IBD

Maitreyi Raman, University of Calgary

Objectives:

- Describe the impact of dietary fiber on the GI mucosa
- Discuss the evidence for dietary fiber restriction in IBD
- Discuss practical strategies to optimize dietary intake in Crohn's disease

3:20 - 3:25 pm

Q&A

3:25 - 3:45 pm

Fatty Liver: What You Need to Know and What You Need to Do

Jessi Daniels, GI Medical Research & Associates Inc.

Objectives:

- Develop a diagnostic approach for fatty liver disease
- Prescribe appropriate treatment recommendations
- Discuss new developments in the management of fatty liver disease

3:45 - 3:50 pm

Q&A

3:50 - 4:10 pm

HCC: The Team Approach

Amy Baker, GI Medical Research & Associates Inc.

Objectives:

- Identify how to screen for hepatocellular carcinoma and how to confirm the diagnosis
- Appraise treatments available for hepatocellular carcinoma
- Assess the nurse's role in the coordination of care for hepatocellular carcinoma

4:10 - 4:15 pm

Q&A

4:15 - 4:20 pm

Closing Comments

4:30 - 5:00 pm

Break

Keynote Session

5:00 - 6:00 pm

Alcoholic Liver Disease: A Tale of Two Maladies

Mount Temple C

Michael Lucey, University of Wisconsin

Moderator: Robert Bailey, Royal Alexandra Hospital

Objectives

- Identify the definition of alcohol use disorder and alcoholic liver disease
- Recognize the role of excess alcohol use in the pathogenesis of alcoholic liver disease
- Formulate an approach to management that treats both the addiction to alcohol and the end-organ damage

6:00 pm -

BBQ Dinner and Dance

Brewster Dance Barn

Saturday, May 27, 2017

7:00 - 7:30 am

Delegate Breakfast

Heritage Hall

Symposium

7:30 - 8:30 am

Managing Crohn's Disease: Has It Just Become Easier?

Mount Temple C

Moderator: Vipul Jairath, Western University

Objectives:

- Discuss the safety and efficacy of new therapies for Crohn's Disease
- Describe how new agents are positioned in the treatment algorithm
- Discuss the real world experience in the clinic setting

7:30 - 7:35 am

Introduction

7:35 - 7:45 am

Interleukin 12 and Interleukin 23 Have a Major Role in IBD

Vipul Jairath, Western University

7:45 - 8:00 am

Manipulating Interleukins as an Important Biologic Target in the Management of Crohn's Disease

Stephen Hanauer, Northwestern University

8:00 - 8:10 am

The Alberta Experience: Real World Clinical Outcomes with Anti-IL12/23 Agents in Crohn's Disease

Christopher Ma, University of Calgary

8:10 - 8:20 am

An Updated Management Algorithm of Crohn's Disease

Vipul Jairath, Western University

8:20 - 8:30 am

Discussion

This symposium was co-developed with Janssen Inc. and was planned to achieve scientific integrity, objectivity and balance.



8:30 - 8:45 am

Break

Plenary Session #1

8:45 - 10:45 am

Excellence in Clinical Management: Part 1

Mount Temple C

*Moderators: Anand Bala, Grey Nuns Hospital;
and Christian Turbide, University of Calgary*

8:45 - 8:55 am

Opening Remarks

8:55 - 9:25 am

When Can You Be Certain Your Therapy of Choice Isn't Working and Needs a Change? Then Do You Change the Dose or Change the Drug?

Stephen Hanauer, Northwestern University

Objectives:

- Review assessment of clinical endpoints
- Discuss therapeutic drug monitoring in the setting of inadequate response
- Review therapeutic drug monitoring to assess loss of response

9:25 - 9:55 am

Detection at Colonoscopy: How Good Can It Get?

Douglas Rex, Indiana University

Objectives:

- Review the definition of the adenoma detection rate (ADR)
- Discuss device and non-device methods to improve ADR

9:55 - 10:25 am

Misplaced Priorities and Barrett's Esophagus

Nicholas Shaheen, University of North Carolina at Chapel Hill

Objectives:

- Identify the epidemiology of Barrett's esophagus and esophageal adenocarcinoma
- Discuss the correct management of patients with Barrett's esophagus

10:25 - 10:55 am

Non-alcoholic Fatty Liver Disease 2017 Update

Zobair Younossi, Inova Fairfax Hospital

Objectives:

- Review the most up to date information about epidemiology and non-alcoholic fatty liver disease (NAFLD)
- Review the current state of the art diagnosis of non-alcoholic fatty liver disease
- Review current and future treatment of non-alcoholic steatohepatitis

10:55 - 11:10 am

Break

Plenary Session #2

11:10 am - 12:30 pm

Focus on Canadian Research and Clinical Practice

Mount Temple C

*Moderators: Tara Chalmers-Nixon, Elk Valley Hospital/
Crownsnest Pass Hospital; and Maitreyi Raman,
University of Calgary*

11:10 - 11:40 am

Next Generation Biologic Therapy in IBD: What does the future hold

Remo Panaccione, University of Calgary

Objectives:

- Discuss new treatments in IBD
- Review the latest data that will impact your clinical practice in 2017 and beyond
- Discuss positioning of new therapies in IBD

11:40 - 12:10 pm

Therapeutic Manipulation of the Gut Microbiota in Patients with IBD

Karen Madsen, University of Alberta

Objectives:

- Understand the role the gut microbiome has in the pathogenesis of IBD
- Gain an understanding of how diet influences the microbiome
- Describe how diet could potentially be used to manipulate the microbiome and treat IBD

12:10 - 12:30 pm

The Digestive Health SCN: Your Strategic Clinical Network

Gilaad Kaplan, University of Calgary

Louise Morrin, Alberta Health Services

12:30 - 1:30 pm

Family Lunch
Delegate Lunch

*Lago Restaurant
Heritage Hall*

Concurrent Symposia

1:00 - 2:00 pm

Approaches Associated with More or Less Successful Implementation of HCV Elimination Strategies: A Tale of 2 Provinces

Mount Temple A

Lisa Barrett, Dalhousie University

Moderator: Robert Bailey, Royal Alexandra Hospital

Objectives:

- Describe HCV elimination plans in two provinces
- Review challenges and facilitators to implementation in two provinces

This symposium was co-developed with Merck and was planned to achieve scientific integrity, objectivity and balance.



1:00 - 2:00 pm

MED Talks - IBD Evolution: Science, Strategies & Clinical Practice

Mount Temple C

Moderator: Brendan Halloran, University of Alberta

Objectives:

- Discuss the benefit/risks of biologics when speaking with patients
- Review pre-conception care and pregnancy in IBD
- Discuss IBD and pregnancy management in Alberta

1:00 - 1:05 pm

Opening Remarks

1:05 - 1:20 pm

Having IBD and Getting Pregnant: What Do I Need to Know in 2017

C. Janneke van der Woude, Erasmus University Medical Centre, Rotterdam

1:20 - 1:35 pm

IBD and Pregnancy Management in Alberta: Cutting-Edge Provincial Programs

Cynthia Seow, University of Calgary

1:35 - 1:45 pm

Discussing Benefit/Risks of Biologics When Speaking With Patients

Remo Panaccione, University of Calgary

1:45 - 2:00 pm

Interactive Panel Discussion

This symposium was co-developed with Takeda Canada Inc. and was planned to achieve scientific integrity, objectivity and balance.



Concurrent Meetings		
2:00 - 3:30 pm	ASG Annual General Meeting	<i>Mount Temple A</i>
2:00 - 3:30 pm	Fellows' Exam Prep Course	<i>Lakeshore/Beehive Room</i>
3:00 - 6:00 pm	Free Time	
6:00 - 7:00 pm	Reception	<i>Victoria Foyer</i>
7:00 pm -	ASG Night and Dinner	<i>Victoria Ballroom</i>
Keynote Presentation		
This Wild Spirit: Women in the Rocky Mountains of Canada		

Special Guest Speaker: Colleen Skidmore, University of Alberta

Sunday, May 28, 2017

7:00 - 7:30 am

Delegate Breakfast

Heritage Hall

Concurrent Symposia

7:30 - 8:30 am

Only if HCV Was So Simple: Unique Patient Populations

Mount Temple A

Mark Swain, University of Calgary

Michael Lucey, University of Wisconsin

Moderator: Robert Bailey, Royal Alexandra Hospital

Objectives:

- Review current and emerging treatment options for HCV using a case based approach
- Demonstrate the application of new HCV therapies in specific patient populations
- Identify the impact of new agents on HCV liver transplant

This symposium was co-developed Gilead Sciences Canada and was planned to achieve scientific integrity, objectivity and balance.



7:30 - 8:30 am

Keep CALM and Treat-To-Target: Optimizing IBD Care Today and Tomorrow

Mount Temple C

John Marshall, McMaster University

Moderator: Remo Panaccione, University of Calgary

Objectives:

- Discuss Treat-to-Target concepts in IBD: new data
- Review the methods of optimizing therapy in 2017
- Assess and explore future therapeutic options

This symposium was co-developed AbbVie Canada Inc. and was planned to achieve scientific integrity, objectivity and balance.



8:30 - 8:45 am

Room Change

Plenary Session #3

8:45 - 9:45 am

IBD at the Summit. Keeping Your Clinical Practice at Its Peak

Mount Temple C

*Moderators: Robert Bailey, Royal Alexandra Hospital; and
Richard Fedorak, University of Alberta*

8:45 - 9:45 am

Panel Discussion

Vipul Jairath, Western University

John Marshall, McMaster University

*C. Janneke van der Woude, Erasmus University Medical Centre,
Rotterdam*

Remo Panaccione, University of Calgary

9:45 - 10:00 am

Break

Plenary Session #4

10:00 - 11:30 am

Excellence in Clinical Management: Part 2

Mount Temple C

Moderator: Carla Coffin, University of Calgary

10:00 - 10:30 am

Ask the Expert - Interactive Case-Based Approach to NAFLD

Zobair Younossi, Inova Fairfax Hospital

Samuel Lee, University of Calgary

Robert Bailey, Royal Alexandra Hospital

Objectives:

- Assess patients at risk of NAFLD
- Review diagnostic lab tests/imaging in assessing NAFLD
- Discuss approach and evidence for current nutrition, lifestyle, surgical pharmacological management

10:30 - 11:00 am

Regimens and Resistance: Interpreting and Implementing Global Guidelines in HCV

Lisa Barrett, Dalhousie University

Objectives:

- Describe new HCV resistance data from EASL
- Assess integration into new practice guidelines
- Discuss implications for broad implementation and clinical impact

11:00 - 11:30 am

Colonoscopic Polypectomy: Toward Maximum Efficacy and Safety

Douglas Rex, Indiana University

Objectives:

- Review the correct endoscopic assessment and description of lateral spreading tumors
- Employ tools and methods for improving the safety and efficacy of endoscopic mucosal resection

11:30 - 11:35 am

Conference Closing

11:35 am -

Delegate Travel / Lunch on Own

SPONSORS

Platinum Sponsors

abbvie



Silver Sponsors



Bronze Sponsors





Contact

ASG@buksa.com
www.albertagastro.ca



Conference Secretariat

BUKSA Strategic Conference Services
Suite 307, 10328 - 81 Avenue, NW
Edmonton, AB T6E 1X2
Tel 780.436.0983
Fax 780.437.5984
Email adds@buksa.com
www.albertagastro.ca/adds/